FDA alignment achieved on pivotal study design supporting a planned Biologics License Application (BLA) submission -- 30-patient pivotal study initiated, evaluating seizure reduction and ...
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 Earnings Call Transcript March 24, 2026 BioCardia, Inc. beats earnings expectations.
Japan’s move to conditionally approve two induced pluripotent stem cell derived therapies marks a significant development for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results